Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters
will be presented at the 24th Annual Meeting of the Society of
Urologic Oncology (SUO 2023), where they will demonstrate the
clinical performance of Veracyte’s Decipher Prostate Genomic
Classifier in identifying patients whose prostate cancer is likely
to progress and require treatment. Collectively, the posters will
report data from more than 60,000 patients. The meeting will take
place in Washington, DC, from November 28 to December 1.
The American Cancer Society estimates that there will be nearly
290,000 new cases of prostate cancer in the U.S. this year. An
ongoing challenge in the management of prostate cancer is
distinguishing between patients whose tumors require careful
monitoring, known as active surveillance, and those who require
intervention. Routinely used clinical factors, such as Gleason
score and prostate-specific antigen (PSA) level, are not sufficient
to determine which prostate cancers are likely to progress and
which are not.
“These presentations by users of the Decipher Prostate Genomic
Classifier will add to the growing body of clinical evidence
supporting the use of the test to help physicians guide care for
their patients with prostate cancer,” said Elai Davicioni, Ph.D.,
Veracyte’s medical director for Urology. “This breadth of
real-world data truly distinguishes our genomic classifier from
other molecular tests available today and serves as a strong
foundation for using Decipher results to provide a more complete
understanding of each patient’s cancer for more personalized
care.”
The following posters will be presented at the SUO 2023 meeting
on Friday, December 1:
Title: Assessing molecular heterogeneity of prostate
cancer biopsy sampling: Insights from the MAST trial
Presenter: Tarek Ajami, M.D., University of Miami
Poster: #214 Time: 10 a.m. to 11 a.m. ET
Title: Decipher® Genomic Classifier on initial prostate
biopsy is associated with Gleason score upgrading on final radical
prostatectomy pathology Presenter: John Sheng, M.D.,
Washington University School of Medicine in St. Louis
Poster: #226 Time: 12:45 p.m. to 1:45 p.m. ET
Title: Decipher® Genomic Classifier score on initial
biopsy is associated with progression from active surveillance to
treatment in prostate cancer Presenter: John Sheng, M.D.,
Washington University School of Medicine in St. Louis
Poster: #237 Time: 1:45 p.m. to 2:45 p.m. ET
Title: Does genomic risk score at biopsy correlate with
focality of disease at radical prostatectomy: Implications for
focal therapy candidates Presenter: Jenna Winebaum, M.D.,
University of California, San Francisco Poster: #189
Time: 9 a.m. to 10 a.m. ET
Title: Grade and volume progression and its association
with the Decipher Genomic Classifier using patients enrolled in a
prospective active surveillance protocol Presenter: Archan
Khandekar, M.D., University of Miami Poster: #219
Time: 12:45 p.m. to 1:45 p.m. ET
Title: Molecular correlates with PSMA expression in
primary prostate cancer Presenter: Adam B. Weiner, M.D.,
University of California, Los Angeles Poster: #201
Time: 10 a.m. to 11 a.m. ET
Title: Understanding population-wide genomic risk
distribution and integrating clinical-genomic risk for
prognostication in patients with clinically localized prostate
cancer Presenter: Udit Singhal, M.D., University of Michigan
Poster: #200 Time: 9 a.m. to 10 a.m. ET
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that the breadth of real-world
data supporting the Decipher Prostate Genomic Classifier serves as
a strong foundation for using Decipher results to provide a more
complete understanding of each patient’s cancer for more
personalized care. Additional factors that may impact these
forward-looking statements can be found under the caption “Risk
Factors” in our Annual Report on Form 10-K filed on March 1, 2023,
and our Quarterly Report on Form 10-Q filed for the three months
ended June 30, 2023. Copies of these documents, when available, may
be found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
Veracyte, the Veracyte logo, and Decipher are registered
trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and
selected countries.
Decipher Prostate is available in the US as part of Veracyte’s
CLIA-validated laboratory developed test (LDT) service. This test
has not been cleared or approved by the FDA. Veracyte, the Veracyte
logo, and Decipher are registered trademarks of Veracyte, Inc., and
its subsidiaries in the U.S. and selected countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231122731608/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Grafico Azioni Veracyte (NASDAQ:VCYT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Veracyte (NASDAQ:VCYT)
Storico
Da Giu 2023 a Giu 2024